![Genmab A/S Website](https://cdn.finchat.io/665704.png)
Genmab A/S
CPSE-GMAB
Company Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Name
Genmab A/S
CEO
Dr. Jan G.J. van de Winkel Ph.D.
Website
www.genmab.com
Sector
Biotechnology
Year Founded
1999
Profile
Market Cap
DKK 118.1B
EV
DKK 103.39B
Shares Out
63.49M
Revenue
DKK 19.02B
Employees
2,526
Margins
Gross
96.95%
EBITDA
33.99%
Operating
32.57%
Pre-Tax
39.55%
Net
29.13%
FCF
34.26%
Returns (5Yr Avg)
ROA
18.77%
ROTA
21.54%
ROE
20.89%
ROCE
23.64%
ROIC
77.64%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
DKK 2,409.94
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
DKK 15.73B
Net Debt
-DKK 14.71B
Debt/Equity
0.03
EBIT/Interest
176.94
Growth (CAGR)
Rev 3Yr
37.46%
Rev 5Yr
42.83%
Rev 10Yr
38.56%
Dil EPS 3Yr
30.42%
Dil EPS 5Yr
34.97%
Dil EPS 10Yr
42.12%
Rev Fwd 2Yr
21.66%
EBITDA Fwd 2Yr
20.64%
EPS Fwd 2Yr
21.86%
EPS LT Growth Est
21.69%
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—